China
Africa
Explore chapters and articles related to this topic
Antibody-Based Therapies
Published in David E. Thurston, Ilona Pysz, Chemistry and Pharmacology of Anticancer Drugs, 2021
Tislelizumab, developed by Beigene, was conditionally approved by the Chinese FDA in 2019 for the treatment of patients with relapsed or refractory classical Hodgkin’s lymphoma after at least second-line chemotherapy. Full approval will be granted based on confirmatory randomized clinical trials that are presently underway. It is currently being investigated in Phase III clinical trials for the treatment of nasopharyngeal, oesophageal, and small-cell lung cancers. Also, Phase II studies are underway in a number of other indications including chronic lymphocytic leukemia, lymphoma, and lung cancer, and Phase I trials have started in hematological malignancies, and ovarian and renal cancer. In China, tislelizumab will be sold under the brand name “Baize’an”.
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
Published in mAbs, 2023
Mengzhen Jiang, Man Liu, Guodi Liu, Jiawen Ma, Lixin Zhang, Shenlin Wang
Developed by Beigene, Ltd., tislelizumab was approved by the NMPA in 2019. It was developed to exhibit less binding to the Fc-γ receptor 1,145 the interactions of which have negative effect on anti-cancer activity by the anti-PD-1 mAbs.146 Tislelizumab is used to treat hepatocellular carcinoma, Hodgkin’s lymphoma, urothelial carcinoma, and NSCLC.81,84,108,147,148 Heo and colleagues solved the PD-1–tislelizumab-Fab structure (PDB:7BXA,38 PDB:7CGW39, which revealed that, unlike other mAbs that recognize the PD-1 loop region, tislelizumab mainly associates with the β-sheet of PD-1, closely mimicking PD-L1-PD-1 binding. In particular, the three LCDRs and the HCDR3 bind PD-1 via several H-bonds and many van der Waals contacts. The binding of tislelizumab to PD-1 sterically hinders the binding of PD-L1 to PD-1.39
Recent advances in immune-based approaches for the treatment of esophagogastric cancer
Published in Expert Opinion on Emerging Drugs, 2022
C. S. Weadick, A. G. Duffy, R. J. Kelly
The use of anti-PD-1 therapies in ESCC has also been investigated in the second line setting, as monotherapy. ATTRACTION-3 first looked at the use of nivolumab in advanced ESCC [62]. It found an overall survival benefit of 2.5 months (10.5 mo versus 8.0 mo). This benefit was also seen, as discussed above, with pembrolizumab in KEYNOTE-181 [50]. Newer anti-PD-1 include tislelizumab, which was part of the RATIONALE-302 study [63]. This phase III trial compared tislelizumab with investigators choice chemotherapy. It demonstrated significant improvement in OS in the intention to treat population (median OS: 8.6 vs 6.3 m) and in the PD-L1 + positive population (median OS: 10.3 vs 6.8 m). Treatment with tislelizumab was also associated with higher overall response rates and longer duration of response. Overall these data highlight that immunotherapy-based approaches are a good option for patients with ESCC in both the first- and second-line setting.
Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma
Published in Expert Opinion on Pharmacotherapy, 2021
Anna Wolska-Washer, Piotr Smolewski, Tadeusz Robak
Tislelizumab (BGB-A317, Baize’an, BeiGene) is an anti-PD-1 monoclonal antibody approved by China’s National Medical Products Administration for the treatment of relapsed/refractory classical Hodgkin lymphoma and various solid tumors [101]. It is currently being studied in a cohort of T- and NK-cell lymphomas of an estimated enrollment of 90 subjects in an ongoing phase 2 trial [102]. A preliminary evaluation of 44 patients from China, Italy, France, and Taiwan revealed an ORR of 20.5% with three CRs in patients with PTCL, NOS. Median DOR was 8.2 months, but one patient in CR maintained the response for 11.2 months. The most common grade ≥3 AEs were neutropenia (9.1%), anemia (6.8%), thrombocytopenia (6.8%), pneumonia (4.5%), and pyrexia (4.5%). Approximately 40% of patients experienced some immune-related AEs, such as pruritus (11.4%), erythema (4.5%), hypothyroidism (4.5%), and rash (4.5%). Adverse events led to treatment delays or discontinuation in 18 patients (40.9%). The authors advocate for the need of combination therapies with tislelizumab, as monotherapy demonstrated only modest activity in T- and NK-cell lymphomas.